Company intelligence / Profile preview
Guangzhou Nanxin Pharmaceutical
Guangzhou, Guangdong Sheng / Province, Chinanucien.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Guangzhou Nanxin Pharmaceutical is a Chinese pharmaceutical company focused on the development and commercialization of small molecule drugs. Its portfolio includes approved products such as benazepril hydrochloride/hydrochlorothiazide for hypertension and peramivir for influenza. The company also has preclinical programs targeting infectious diseases and metabolic disorders, including candidates modulating TGF-beta 1 signaling. It is active in clinical trials with at least one program reaching Phase 2.
- Therapeutic areas
- CardiovascularInfectious Diseases
- Modalities
- Small molecule drug
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Guangzhou Nanxin Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Nanxin Pharmaceutical.